TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT05463263

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing STP938 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 3 US locations.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

STP938 (DRUG): Small molecule

Drugs / treatments
STP938
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

NCT05463263

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is comparing STP938 against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 3 US locations.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

STP938 (DRUG): Small molecule

Drugs / treatments: STP938

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 180 patients

Primary endpoint: Safety and Tolerability (Phase 1 / Dose Escalation); Objective Response Rate (ORR) (Phase 2 / Dose Expansion)

Ages: 18 Years to —

Start date: 2022-08-03 | Est. completion: 2026-12

Locations

3 US sites · 15 total

Colorado, Florida, New York

Contact

Maureen Higgins | STP938-101@step-ph.com | +33 1 86 26 43 56

Sponsor: Step Pharma, SAS (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05463263

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.